T(
Therapeutic Areas
Chrysalis BioTherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TP508 (Chrysalin™, rusalatide acetate) | Acute Respiratory Distress Syndrome (ARDS) from COVID-19 and non-COVID causes (infection, inflammation, traumatic injury) | Phase 1/2 |
Leadership Team at Chrysalis BioTherapeutics
DH
Darrell H. Carney, PhD
President, CEO and Board Chair
JB
Jerry Baty, JD, CPA, MBA
Chief Financial Officer
LS
Laurie Sower, PhD
Executive Vice President
GM
Gerald M Fuller, PhD
VP of Research
SP
Steven Pikulin, PhD
Director, Product Development /CMC
JT
James T. Ryaby, PhD
Member, Board of Directors
JS
Jeffery Sheldon, MBA
Member, Board of Directors